FGF19 promotes progression of prostate cancer

  title={FGF19 promotes progression of prostate cancer},
  author={Hirotaka Nagamatsu and Jun Teishima and Keisuke Goto and Hiroyuki Shikuma and Hiroyuki Kitano and Koichi Shoji and Shogo Inoue and Akio Matsubara},
  journal={The Prostate},
Fibroblast growth factor (FGF) signaling pathways have been reported to play important roles in prostate cancer (PCa) progression. FGF19 is one of a subfamily of FGFs that circulate in serum and act in an endocrine manner. Our objective was to investigate its role in the progression of PCa. 
Fibroblast Growth Factor Family in the Progression of Prostate Cancer
The current knowledge regarding the role of FGFs and FGFRs—including paracrine F GFs, endocrine FGFS, and FG FRs—in the development and progression of PCa is discussed, focusing on the representative molecules in each subfamily.
The FGF/FGFR System in the Physiopathology of the Prostate Gland.
Experimental evidence indicates that FGFs play a complex role in the physiopathology of the prostate gland that ranges from essential functions during embryonic development to modulation of neoplastic transformation andsection of the molecular landscape modulated by the FGF family will facilitate ongoing translational efforts directed toward prostate cancer therapy.
FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas
Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous
Making way for suppressing the FGF19/FGFR4 axis in cancer.
Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.
Upregulation of FGF 19 in lung adenocarcinoma and predicts poor prognosis
Analysis of the expression of FGF19 in LAC tissues and corresponding normal tissues suggested that up-regulation of F GF19 might potentially be an effective therapeutic approach for LAC.
Advances and challenges in targeting FGFR signalling in cancer
The increasing understanding of the differences between diverse mechanisms of oncogenic activation of FGFR, and the factors that determine response and resistance to FGFR targeting are discussed.
Fibroblast growth factor–mediated crosstalk in cancer etiology and treatment
Unraveling the complexities of FGF signalling between the distinct cell types of a tumor may identify additional opportunities for FGF‐targeted compounds in therapy and could help combat drug resistance.
Upregulation of Fibroblast Growth Factor 19 Is Associated with the Initiation of Colorectal Adenoma
Observations indicate that the FGF19/FGFR4 pathway may be involved in the development of neoplasia, and that FGF 19 may be a valuable diagnostic marker for the identification of patients with colorectal adenomas.
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis
A compelling biologic rationale exists for the development of anti-FGF/FGFR agents for the inhibition of tumor angiogenesis in cancer therapy, including FGFR selective and nonselective small-molecule tyrosine kinase inhibitors, anti-FGFR antibodies, and FGF ligand traps.


The role of fibroblast growth factors and their receptors in prostate cancer.
The effects of increased FGF receptor signaling are wide ranging and involve both the cancer cells and surrounding stroma, including the vasculature, all of which can enhance tumor progression and clinical aggressiveness.
Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression.
It is shown that FGF19 is expressed in primary and metastatic prostate cancer tissues, where it functions as an autocrine growth factor, supporting the concept that therapies targeting FGFR signaling may have efficacy in prostate cancer and highlighting FGF 19 as a relevant endocrine FGF in this setting.
Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
  • D. Giri, F. Ropiquet, M. Ittmann
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
There is both an increase in FGF2 concentration in prostate cancers and an increased expression of a receptor capable of responding to this growth factor, establishing a potential paracrine stimulation of prostate cancer cells by the surrounding stromal cells, which may play an important role in prostate cancer progression.
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype
It is demonstrated that increased FGFR4 and reduced Sef may be critical FGF alterations associated with prostate cancer progression and may also have a role in the tumour response to FGFR inhibition and warrants further investigation.
Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism.
This minireview focuses on the physiological and pathophysiological significance of FGF23 in phosphate and bone metabolism and its role in chronic kidney disease-mineral and bone disorder.
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
The model of FGF system as valid target for therapy in CaP is supported and synergistic effects on in vitro cell growth (proliferation and colony formation) by combining sFGFR expression and treatment with either Paclitaxel (Taxol®) or γ-irradiation are confirmed.
Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
FGF19/FGFR4 cross-talk with beta-catenin and that pathway intervention reduces tumor growth is highlighted and wild-type beta-Catenin is accessible for modulation.
Selective over‐expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer
Evidence of selective over‐expression of FGFR1 and FGFR4 in clinical prostate cancer is suggested and the notion of targeted inhibition of these receptors to disrupt FGF signalling is supported.
Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence
It is indicated that FGF9 can stimulate proliferation and invasion in prostate cancer cells, thus FGF 9 could be a candidate of a predictive factor for recurrence after radical prostatectomy.
The Klotho gene family as a regulator of endocrine fibroblast growth factors